Literature DB >> 34431782

Prescribe an SGLT2 inhibitor for heart failure in the absence of diabetes?

Debra Koenigsberger1, Alexander Marquez1, Pamela R Hughes1.   

Abstract

An RCT demonstrates that dapagliflozin produces better cardiovascular outcomes than placebo for heart failure patients with and without diabetes.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34431782      PMCID： PMC8407228          DOI： 10.12788/jfp.0235

Source DB:  PubMed          Journal:  J Fam Pract        ISSN： 0094-3509            Impact factor:   0.493


  9 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

Review 2.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.

Authors:  Subodh Verma; John J V McMurray
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

3.  Lifetime risk for developing congestive heart failure: the Framingham Heart Study.

Authors:  Donald M Lloyd-Jones; Martin G Larson; Eric P Leip; Alexa Beiser; Ralph B D'Agostino; William B Kannel; Joanne M Murabito; Ramachandran S Vasan; Emelia J Benjamin; Daniel Levy
Journal:  Circulation       Date:  2002-12-10       Impact factor: 29.690

4.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  John J V McMurray; Scott D Solomon; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Inder S Anand; Jan Bělohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andrej Dukát; Junbo Ge; Jonathan G Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Mark C Petrie; Pham N Vinh; Morten Schou; Sergey Tereshchenko; Subodh Verma; Claes Held; David L DeMets; Kieran F Docherty; Pardeep S Jhund; Olof Bengtsson; Mikaela Sjöstrand; Anna-Maria Langkilde
Journal:  N Engl J Med       Date:  2019-09-19       Impact factor: 91.245

5.  Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.

Authors:  Michael E Nassif; Sheryl L Windsor; Fengming Tang; Yevgeniy Khariton; Mansoor Husain; Silvio E Inzucchi; Darren K McGuire; Bertram Pitt; Benjamin M Scirica; Bethany Austin; Mark H Drazner; Michael W Fong; Michael M Givertz; Robert A Gordon; Rita Jermyn; Stuart D Katz; Sumant Lamba; David E Lanfear; Shane J LaRue; JoAnn Lindenfeld; Michael Malone; Kenneth Margulies; Robert J Mentz; R Kannan Mutharasan; Michael Pursley; Guillermo Umpierrez; Mikhail Kosiborod
Journal:  Circulation       Date:  2019-09-16       Impact factor: 29.690

6.  Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.

Authors:  Salim S Virani; Alvaro Alonso; Emelia J Benjamin; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Amanda Marma Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Christina M Shay; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Lisa B VanWagner; Connie W Tsao
Journal:  Circulation       Date:  2020-01-29       Impact factor: 29.690

Review 7.  Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Jacob A Udell; Julie A Lovshin; David Z I Cherney
Journal:  Circulation       Date:  2017-10-24       Impact factor: 29.690

8.  2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.

Authors:  Sandeep R Das; Brendan M Everett; Kim K Birtcher; Jenifer M Brown; James L Januzzi; Rita R Kalyani; Mikhail Kosiborod; Melissa Magwire; Pamela B Morris; Joshua J Neumiller; Laurence S Sperling
Journal:  J Am Coll Cardiol       Date:  2020-08-05       Impact factor: 24.094

Review 9.  Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure.

Authors:  Raktim K Ghosh; Gopal Chandra Ghosh; Manasvi Gupta; Dhrubajyoti Bandyopadhyay; Tauseef Akhtar; Prakash Deedwania; Carl J Lavie; Gregg C Fonarow; Ashish Aneja
Journal:  Am J Cardiol       Date:  2019-09-10       Impact factor: 2.778
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.